Biocryst Pharma Inc (BCRX) Stock Price, Quote & News

Company Profile

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 919 859 1302

Fax: 919 859 1314

Website: www.biocryst.com

Address:

4505 Emperor Boulevard, Suite 200, Durham, United States

RowdyRoundy Apr. 25 at 4:17 PM

$BCRX I think the NTLA data will be good but might not be stellar enough. Due to the high cost and potential unknown risks they want it perfect but it doesn’t always work and durability long term as a true one and done is still in question. interesting that during market hours yesterday they traded 7.78 mil shares and it fell sharply. They are way up after hours but on 1.24 mil volume.

0 · Reply

MaxNoob Apr. 25 at 1:07 PM

$BCRX All the worry about Nutella….in reality it’s not going to be a big deal IMO. Now does that mean MMs wont use it to drive fear? Of course not.its a prime opportunity. just look at the posts on here.

0 · Reply

Ttubular Apr. 25 at 12:42 PM

$BCRX I’m thinking if NTLA results are good then we take a hit on Monday. I think patients on orladeyo already will mostly stay. But I’m thinking this will hurt our growth going forward. Also I think it greatly reduces our chances for a BO. Monday will be a big day for us. Hoping for the best. What is everyone’s opinion on this.

3 · Reply

Ttubular Apr. 25 at 12:21 PM

$BCRX if NTLA results are good what is our worst case scenario on price for Monday ? Under $8 or does this actually help us?

0 · Reply

Fergus20 Apr. 25 at 12:46 AM

$BCRX HAHAHAHAHAHA!!! Solid after hours session!

1 · Reply

Chris2bucks4life Apr. 25 at 12:33 AM

$BCRX only a 3 million buy after hours lol

0 · Reply

Theobviouschoice Apr. 25 at 12:31 AM

$BCRX Large AH buy $3M

1 · Reply

ragman1 Apr. 24 at 11:55 PM

$BCRX if the data was bad, they would have released it after hours today. So what's the thinking?...good data helps with a bo?...or hurts the entire field? It seems like there are those who believe it's a positive based on the after hours action.

0 · Reply

Markispolish717 Apr. 24 at 11:46 PM

$BCRX we are fucked if that data is good on Monday

2 · Reply

USDollar Apr. 24 at 11:34 PM

$BCRX limited risk from INTLA •INTLA = potential functional cure, but adoption will be slow, gated, and very cautious and upfront huge cost. •BCRX = steady chronic revenue, limited disruption risk but capped upside.

1 · Reply

BioCryst to Report First Quarter 2026 Financial Results on May 6

Apr 6, 2026, 7:00 AM EDT - 19 days ago

BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer

Apr 3, 2026, 7:00 AM EDT - 22 days ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 3, 2026, 9:10 AM EST - 7 weeks ago

BioCryst Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 8:30 AM EST - 2 months ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 26, 2026, 7:00 AM EST - 2 months ago

BioCryst Reports Full Year 2025 Financial Results and Provides Business Update

Feb 17, 2026, 7:00 AM EST - 2 months ago

BioCryst to Present at Upcoming Investor Conference

Feb 11, 2026, 7:00 AM EST - 2 months ago

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting

Feb 5, 2026, 7:01 AM EST - 2 months ago

BioCryst to Report Fourth Quarter 2025 Financial Results on February 26

Jan 23, 2026, 9:00 AM EST - 3 months ago

BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema

Jan 12, 2026, 1:30 PM EST - 3 months ago

BioCryst Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 3 months ago

BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range

Jan 6, 2026, 7:00 AM EST - 3 months ago

BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 12, 2025, 7:06 AM EST - 4 months ago

FDA expands approval of BioCryst's rare disease drug for use in young children

Dec 12, 2025, 7:00 AM EST - 4 months ago

BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to

Dec 3, 2025, 7:00 AM EST - 5 months ago

BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition

Nov 19, 2025, 12:00 PM EST - 5 months ago

BioCryst Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 6, 2025, 8:00 AM EST - 6 months ago

BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)

Nov 3, 2025, 8:30 AM EST - 6 months ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 3, 2025, 7:00 AM EST - 6 months ago

BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 23, 2025, 7:00 AM EDT - 6 months ago

BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

Oct 20, 2025, 7:00 AM EDT - 6 months ago

BioCryst to Report Third Quarter 2025 Financial Results on November 3

Oct 17, 2025, 3:20 PM EDT - 6 months ago

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

ATXS

Oct 14, 2025, 12:20 PM EDT - 6 months ago

BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'

ATXS

Oct 14, 2025, 8:00 AM EDT - 6 months ago

BioCryst Pharmaceuticals Transcript: M&A Announcement

Oct 14, 2025, 7:35 AM EDT - 6 months ago

BioCryst to buy Astria Therapeutics in $700 million deal

ATXS

Oct 14, 2025, 7:00 AM EDT - 6 months ago

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

ATXS

Oct 1, 2025, 7:00 AM EDT - 7 months ago

BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business

Sep 4, 2025, 9:45 AM EDT - 8 months ago

BioCryst Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Aug 11, 2025, 7:00 AM EDT - 9 months ago

BioCryst Announces Departure of Dr. Helen Thackray

Aug 4, 2025, 8:30 AM EDT - 9 months ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 4, 2025, 7:00 AM EDT - 9 months ago

BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 7:00 AM EDT - 9 months ago

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December

Jul 21, 2025, 7:00 AM EDT - 9 months ago

BioCryst to Report Second Quarter 2025 Financial Results on August 4

Jul 9, 2025, 7:00 AM EDT - 10 months ago

BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit

Jul 7, 2025, 7:00 AM EDT - 10 months ago

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development

Jun 27, 2025, 8:30 AM EDT - 10 months ago

BioCryst Pharmaceuticals Transcript: M&A Announcement

Jun 27, 2025, 7:00 AM EDT - 10 months ago

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

Jun 16, 2025, 7:00 AM EDT - 11 months ago

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

Jun 13, 2025, 7:00 AM EDT - 11 months ago

ORLADEYO® (berotralstat) Approved in Colombia

Jun 9, 2025, 8:40 AM EDT - 11 months ago

BioCryst Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 6, 2025, 7:00 AM EDT - 11 months ago

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

Jun 4, 2025, 4:55 PM EDT - 11 months ago

BioCryst Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 2, 2025, 7:00 AM EDT - 11 months ago

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

May 30, 2025, 7:00 AM EDT - 11 months ago

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages

May 27, 2025, 7:00 AM EDT - 11 months ago

BioCryst to Present at Upcoming Investor Conferences

May 16, 2025, 7:00 AM EDT - 1 year ago

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)

May 14, 2025, 1:40 PM EDT - 1 year ago

BioCryst Pharmaceuticals Transcript: Bank of America 2025 Healthcare Conference

May 14, 2025, 7:00 AM EDT - 1 year ago

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

May 8, 2025, 9:00 AM EDT - 1 year ago

BioCryst Pharmaceuticals Transcript: The Citizens JMP Life Sciences Conference 2025

May 5, 2025, 5:29 PM EDT - 1 year ago

BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors

May 5, 2025, 8:30 AM EDT - 1 year ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q1 2025

May 5, 2025, 7:00 AM EDT - 1 year ago

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 7:00 AM EDT - 1 year ago

BioCryst Appoints Steve Frank to Board of Directors

Apr 21, 2025, 7:00 AM EDT - 1 year ago

BioCryst to Report First Quarter 2025 Financial Results on May 5

Apr 9, 2025, 9:30 AM EDT - 1 year ago

BioCryst Pharmaceuticals Transcript: 24th Annual Needham Virtual Healthcare Conference

Mar 11, 2025, 10:00 AM EDT - 1 year ago

BioCryst Pharmaceuticals Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 5, 2025, 9:10 AM EST - 1 year ago

BioCryst Pharmaceuticals Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 24, 2025, 11:49 AM EST - 1 year ago

BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings

Feb 24, 2025, 8:30 AM EST - 1 year ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 24, 2025, 7:00 AM EST - 1 year ago

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

Feb 24, 2025, 6:00 AM EST - 1 year ago

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to

Feb 12, 2025, 7:00 AM EST - 1 year ago

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

Feb 10, 2025, 8:30 AM EST - 1 year ago

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

Feb 10, 2025, 7:00 AM EST - 1 year ago

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

Jan 14, 2025, 6:00 PM EST - 1 year ago

BioCryst Pharmaceuticals Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 10, 2025, 7:00 AM EST - 1 year ago

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

Jan 7, 2025, 7:00 AM EST - 1 year ago

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 5, 2024, 8:30 AM EST - 1 year ago

BioCryst Pharmaceuticals Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 4, 2024, 2:35 PM EST - 1 year ago

BioCryst Pharmaceuticals Transcript: 7th Annual Evercore ISI HealthCONx Conference

Nov 20, 2024, 5:00 AM EST - 1 year ago

BioCryst Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2024

Nov 4, 2024, 8:30 AM EST - 1 year ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q3 2024

Sep 19, 2024, 12:45 PM EDT - 1 year ago

BioCryst Pharmaceuticals Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 9, 2024, 9:00 AM EDT - 1 year ago

BioCryst Pharmaceuticals Transcript: H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 1:30 PM EDT - 1 year ago

BioCryst Pharmaceuticals Transcript: 2024 Wells Fargo Healthcare Conference

Aug 5, 2024, 8:30 AM EDT - 1 year ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q2 2024

Jun 6, 2024, 9:30 AM EDT - 2 years ago

BioCryst Pharmaceuticals Transcript: Jefferies Global Healthcare Conference

May 20, 2024, 10:30 AM EDT - 2 years ago

BioCryst Pharmaceuticals Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 15, 2024, 5:20 PM EDT - 2 years ago

BioCryst Pharmaceuticals Transcript: BofA Securities 2024 Health Care Conference

May 14, 2024, 3:05 PM EDT - 2 years ago

BioCryst Pharmaceuticals Transcript: 2024 RBC Capital Markets Global Healthcare Conference

May 13, 2024, 12:30 PM EDT - 2 years ago

BioCryst Pharmaceuticals Transcript: The Citizens JMP Life Sciences Conference

May 6, 2024, 8:30 AM EDT - 2 years ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q1 2024

Apr 9, 2024, 10:15 AM EDT - 2 years ago

BioCryst Pharmaceuticals Transcript: 23rd Annual Needham Virtual Healthcare Conference

Mar 28, 2024, 2:30 PM EDT - 2 years ago

BioCryst Pharmaceuticals Transcript: 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference 2024

Mar 12, 2024, 7:30 AM EDT - 2 years ago

BioCryst Pharmaceuticals Transcript: Barclays 26th Annual Global Healthcare Conference 2024

Mar 6, 2024, 10:30 AM EST - 2 years ago

BioCryst Pharmaceuticals Transcript: TD Cowen 44th Annual Health Care Conference

Feb 26, 2024, 8:30 AM EST - 2 years ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q4 2023

Jan 9, 2024, 6:00 PM EST - 2 years ago

BioCryst Pharmaceuticals Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Nov 29, 2023, 12:30 PM EST - 2 years ago

BioCryst Pharmaceuticals Transcript: Piper Sandler 35th Annual Healthcare Conference

Nov 28, 2023, 9:35 AM EST - 2 years ago

BioCryst Pharmaceuticals Transcript: The 6th Annual Evercore ISI HealthCONx Conference

Nov 3, 2023, 1:00 PM EDT - 2 years ago

BioCryst Pharmaceuticals Transcript: R&D Day 2023

Nov 2, 2023, 8:30 AM EDT - 2 years ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q3 2023

Sep 6, 2023, 3:00 PM EDT - 2 years ago

BioCryst Pharmaceuticals Transcript: Wells Fargo Securities Healthcare Conference 2023

Aug 3, 2023, 8:30 AM EDT - 2 years ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q2 2023

May 10, 2023, 6:00 PM EDT - 3 years ago

BioCryst Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2023

May 3, 2023, 8:30 AM EDT - 3 years ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q1 2023

Mar 14, 2023, 9:30 AM EDT - 3 years ago

BioCryst Pharmaceuticals Transcript: Barclays Global Healthcare Conference

Feb 21, 2023, 8:30 AM EST - 3 years ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q4 2022

Jan 10, 2023, 6:00 PM EST - 3 years ago

BioCryst Pharmaceuticals Transcript: JPMorgan Healthcare Conference

Nov 1, 2022, 8:30 AM EDT - 3 years ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q3 2022

Aug 3, 2022, 9:10 PM EDT - 4 years ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q2 2022

May 10, 2022, 10:00 AM EDT - 4 years ago

BioCryst Pharmaceuticals Transcript: Bank of America 2022 Healthcare Conference

May 5, 2022, 9:06 AM EDT - 4 years ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q1 2022

Apr 14, 2022, 10:00 AM EDT - 4 years ago

BioCryst Pharmaceuticals Transcript: Needham 21st Annual Healthcare Conference

Mar 16, 2022, 11:00 AM EDT - 4 years ago

BioCryst Pharmaceuticals Transcript: Barclays Global Healthcare Conference 2022

Feb 23, 2022, 1:27 PM EST - 4 years ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q4 2021

Jan 10, 2022, 10:00 AM EST - 4 years ago

BioCryst Pharmaceuticals Transcript: JPMorgan 40th Annual Healthcare Conference

Nov 3, 2021, 9:00 AM EDT - 4 years ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q3 2021

Sep 10, 2021, 10:00 AM EDT - 5 years ago

BioCryst Pharmaceuticals Transcript: Wells Fargo 2021 Virtual Healthcare Conference

Aug 5, 2021, 8:00 AM EDT - 5 years ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q2 2021

May 6, 2021, 8:00 AM EDT - 5 years ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q1 2021

Feb 25, 2021, 8:00 AM EST - 5 years ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q4 2020

Nov 5, 2020, 8:00 AM EST - 5 years ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q3 2020

Aug 6, 2020, 8:00 AM EDT - 6 years ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q2 2020

May 6, 2020, 8:00 AM EDT - 6 years ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q1 2020

Mar 5, 2020, 8:00 AM EST - 6 years ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q4 2019

Nov 6, 2019, 8:00 AM EST - 7 years ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q3 2019

Aug 6, 2019, 8:00 AM EDT - 7 years ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q2 2019

May 8, 2019, 8:00 AM EDT - 7 years ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q1 2019

Mar 4, 2019, 8:00 AM EST - 7 years ago

BioCryst Pharmaceuticals Earnings Call Transcript: Q4 2018

RowdyRoundy Apr. 25 at 4:17 PM

0 · Reply

MaxNoob Apr. 25 at 1:07 PM

0 · Reply

Ttubular Apr. 25 at 12:42 PM

3 · Reply

Ttubular Apr. 25 at 12:21 PM

$BCRX if NTLA results are good what is our worst case scenario on price for Monday ? Under $8 or does this actually help us?

0 · Reply

Fergus20 Apr. 25 at 12:46 AM

$BCRX HAHAHAHAHAHA!!! Solid after hours session!

1 · Reply

Chris2bucks4life Apr. 25 at 12:33 AM

$BCRX only a 3 million buy after hours lol

0 · Reply

Theobviouschoice Apr. 25 at 12:31 AM

$BCRX Large AH buy $3M

1 · Reply

ragman1 Apr. 24 at 11:55 PM

0 · Reply

Markispolish717 Apr. 24 at 11:46 PM

$BCRX we are fucked if that data is good on Monday

2 · Reply

USDollar Apr. 24 at 11:34 PM

1 · Reply

Ttubular Apr. 24 at 11:23 PM

$BCRX over 400k in AH volume and a lot of big buys. Ther was a buy for 335,000 for almost $3MILL I guess they aren’t scared of that drug dropping data we will c Monday

0 · Reply

Uptrending21 Apr. 24 at 9:42 PM

$BCRX $NTLA CAMBRIDGE, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.(NTLA) , a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the company will report topline clinical data from its global Phase 3 HAELO clinical trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE) on Monday, April 27, 2026 and will host a webcast at 8:00 a.m. ET to discuss the data.

0 · Reply

Money_Mane Apr. 24 at 9:35 PM

$BCRX ok so the sideways chop was bc NTLA is dropping data Monday just got super interesting

1 · Reply

pocketmoney Apr. 24 at 8:32 PM

$BCRX $NTLA

1 · Reply

gdesivir Apr. 24 at 8:28 PM

$BCRX So if Takeda buys Biocryst they will have 75% of the market. Alternatively, if they don't and Navenibert gets approved, they may be left with 25%

1 · Reply

SNOB_ORDER Apr. 24 at 8:10 PM

$BCRX Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026

2 · Reply

Money_Mane Apr. 24 at 8:08 PM

$BCRX it just won’t die. Some institution(s) is gearing up for a catalyst

1 · Reply

MattressMonkey007 Apr. 24 at 8:08 PM

$BCRX … think she did that end of day thingy just for @Money_Mane

1 · Reply

Ttubular Apr. 24 at 8:01 PM

$BCRX nice close .01 off the high. Now Sunday night BO news. I can dream n boy do I dream a lot

0 · Reply

drose0527 Apr. 24 at 8:01 PM

$BCRX look who called the close I believe it was this guy!

2 · Reply

Chris2bucks4life Apr. 24 at 7:57 PM

$BCRX close above 9 please

1 · Reply

milt0n Apr. 24 at 7:18 PM

$BCRX Interesting and encouraging to see. Takhzyro and Haegarda are going to feel more pain when navenibart gets approved. It’s the same mechanism class so it’s low risk for patients and their physicians to switch. Going to an injection that doesn’t hurt every 3-6 months will be a no brainer. Haegarda is probably more vunerable than Takhzyro. You could say that navenibart might even act as a moat around Orladeyo because of reduced switching out to the competition now. N + O = great tag team combination ! Thanks for sharing @SNOB_ORDER

0 · Reply

Market Cap	2.20B
Revenue (ttm)	874.84M
Net Income (ttm)	263.86M
EPS (ttm)	N/A
PE Ratio	6.77
Forward PE	34.39
Profit Margin	30.16%
Debt to Equity Ratio	-4.02

Volume	2,623,700
Avg Vol	5,498,932
Day's Range	N/A - N/A
Shares Out	250.80M
Stochastic %K	31%
Beta	0.70
Analysts	Strong Sell
Price Target	$21.40